Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma



Status:Recruiting
Conditions:Urology
Therapuetic Areas:Nephrology / Urology
Healthy:No
Age Range:18 - Any
Updated:1/19/2019
Start Date:June 2015
End Date:December 2021
Contact:Rainier Therapeutics
Email:clin-ops@rainierrx.com
Phone:925-413-6140

Use our guide to learn which trials are right for you!

A Dose Escalation, Expansion Study of Vofatamab (B-701) Alone, Plus Docetaxel, or Versus Docetaxel in Subjects With Locally Advanced or Metastatic Urothelial Cell Carcinoma Who Have Relapsed After, or Are Refractory to Standard Therapy

This is a Phase 1/2(b), sequential, dose escalation, open-label, randomized expansion,
multicenter, efficacy and safety study of vofatamab alone or in combination with docetaxel,
or versus docetaxel in FGFR3 mutant/fusion subjects with Stage IV, locally advanced or
metastatic UCC who have relapsed after, or are refractory to at least one prior line of
chemotherapy. This study is divided into 3 phases: Phase 1b (Cohort 1), Phase 2 (Cohorts 2
and 3), and Phase 2b (Monotherapy Expansion Phase and Randomized Phase).

This is a Phase 1/2(b), sequential, dose escalation, open-label, randomized expansion,
multicenter, efficacy and safety study of vofatamab alone or in combination with docetaxel,
or versus docetaxel in FGFR3 mutant/fusion subjects with Stage IV, locally advanced or
metastatic UCC who have relapsed after, or are refractory to at least one prior line of
chemotherapy. Vofatamab is a novel monoclonal antibody specific for fibroblast growth factor
receptor 3 (FGFR3) that is being developed to target FGFR3-positive tumors.

This study is divided into 3 phases: Phase 1b (Cohort 1), Phase 2 (Cohorts 2 and 3), and
Phase 2b (Monotherapy Expansion Phase and Randomized Phase).

Key Disease Specific Inclusion Criteria:

1. Stage IV, locally advanced or metastatic (T4b, any N; or any T, N2-3) urothelial
bladder cancer or TCC arising in another location of the urinary tract, including
urethra, ureter, and renal pelvis

2. Histological or cytological diagnosis of UCC.

3. Relapsed after or are refractory to at least one prior line of chemotherapy which has
not included a taxane (with the exception of Cohort 3 of Phase 2 and Phase 2b
Monotherapy Expansion of Phase 2b which will allow the enrollment of patients with
prior treatment with a taxane)

4. Subjects must have received at least one prior chemotherapeutic regimen (at least one
cycle each) for advanced or metastatic/recurrent disease, of which at least one
regimen included a platinum agent (unless contraindicated).

5. Prior neoadjuvant or adjuvant chemotherapy (without a taxane, except Cohort 3 of Phase
2 and Phase 2b Monotherapy Expansion, which will allow the enrollment of subjects with
prior treatment with a taxane) is permitted and will not be counted as first-line
chemotherapy, as long as the subject has not progressed within 12 months of the last
dose.

6. Measurable disease according to Response Evaluation Criteria in Solid Tumors Version
1.1 (RECIST v1.1)

Phase 2 and Phase 2b Specific Inclusion Criteria:

1. Patient must be confirmed to have a FGFR3 genomic alteration at the time of
documentation of advanced disease.

2. Relapsed after or are refractory to an immune checkpoint inhibitor. This inclusion
criterion does not apply if the checkpoint inhibitor is contraindicated.

Main Exclusion Criteria:

- Prior anti-cancer therapy within 2 weeks prior to Cycle 1, Day 1

- Prior treatment with an inhibitor that is targeted primarily to FGFRs

- Clinically significant comorbid medical conditions or lab abnormalities

- History of major bleeding (requiring a blood transfusion ≥ 2 units) not related to a
tumor within the past 12 months

- History of clinically significant coagulation or platelet disorder in the past 12
months

- Currently receiving anticoagulation treatment

- Incomplete healing from wounds from prior surgery

- Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection at
screening

- Presence of positive test results for Hepatitis B or Hepatitis C

- Known history of human immunodeficiency virus (HIV) seropositive status
We found this trial at
14
sites
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Canton, OH
Click here to add this to my saved trials
?
mi
from
Detroit, MI
Click here to add this to my saved trials
?
mi
from
Duarte, CA
Click here to add this to my saved trials
Fort Wayne, Indiana 46845
?
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
?
mi
from
Gilbert, AZ
Click here to add this to my saved trials
?
mi
from
Goodyear, AZ
Click here to add this to my saved trials
?
mi
from
Louisville, KY
Click here to add this to my saved trials
?
mi
from
Miami, FL
Click here to add this to my saved trials
?
mi
from
Olomouc,
Click here to add this to my saved trials
?
mi
from
Rochester, MN
Click here to add this to my saved trials
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
?
mi
from
Syracuse, NY
Click here to add this to my saved trials